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GHRH stimulates GH synthesis and release from the pituitary and exerts direct effects in extrapi-
tuitary tissues. We have previously shown that pretreatment with GHRH reduces cardiomyocyte
apoptosis and improves heart function in isolated rat hearts subjected to ischemia/reperfusion
(I/R). Here, we determinedwhether GHRH given at reperfusion reducesmyocardial reperfusion
injury and investigated themolecular mechanisms involved in GHRH effects. Isolated rat hearts
subjected to I/R were treated at the onset of reperfusion with: 1) GHRH; 2) GHRHGHRH
antagonist JV-1-36; 3) GHRHmitochondrial ATP-dependent potassium channel inhibitor 5-hy-
droxydecanoate; 4) GHRHmitochondrial permeability transition pore opener atractyloside;
5) GHRH phosphoinositide 3-kinase/Akt inhibitor Wortmannin (WM); and 6) GHRHsignal
transducer and activator of transcription-3 inhibitor tyrphostin-AG490 (AG490). GHRH reduced
infarct size at the end of reperfusion and reverted contractility dysfunction in I/R hearts. These
effects were inhibited by either JV-1-36, 5-hydroxydecanoate, atractylosid, WM, or AG490.
Western blot analysis on left ventricles showed GHRH-induced phosphorylation of either the
reperfusion injury salvage kinases (RISK), phosphoinositide 3-kinase/Akt, ERK1/2, and glycogen
synthase kinase-3 or signal transducer and activator of transcription-3, as part of the survivor
activating factor enhancement (SAFE) pathway. GHRH-induced activation of RISK and SAFE
pathways was blocked by JV-1-36, WM, and AG490. Furthermore, GHRH increased the phos-
phorylation of endothelial nitric oxide synthase and AMP-activated protein kinase and pre-
served postischemic nicotinamide adenine dinucleotide (NAD) levels. These results suggest
that GHRH protects the heart from I/R injury through receptor-mediated mechanisms, leading
to activation of RISK and SAFE pathways, which converge on mitochondria and possibly on
AMP-activated protein kinase. (Endocrinology 154: 1624–1635, 2013)
Several studies have suggested an important role for theGH/IGF-I axis in the regulation of cardiac growth and
function, so that excess or deficit of these hormones is
associated with deranged myocardial structure and per-
formance (1, 2). Moreover, GH-releasing peptides, such as
ghrelinandGHsecretagogues (GHSs) (3–5),orghrelingene-
derived products, such as obestatin (6), have been shown to
exert protective effects against cell death and contractile dys-
function in hearts undergoing ischemia/reperfusion (I/R).
These actions likely involve direct binding to cardio-
vascular-specific receptors and activation of signal
transduction pathways conveying the cardioprotective
signal from the sarcolemma to the mitochondria via
enzymes of the so-called reperfusion injury salvage ki-
nase (RISK) pathway (7, 8).
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Until lately, however, the interest on the cardiovascular
effects of thehypothalamichormoneGHRHhasbeenvery
scant. We have recently shown that pretreatment with
GHRH enhanced the postischemic recovery of left ven-
tricular (LV) developed pressure and reduced the devel-
opment of diastolic contracture and infarct size in isolated
rat hearts subjected to I/R (9). The protective effect of
GHRH was confirmed in adult rat ventricular myocytes
and the cardiac cell lineH9c2, onwhichGHRHprevented
apoptosis induced by serum starvation or treatment with
isoproterenol (9). In both cell types, as well as in isolated
rat hearts, these effects involved GHRH receptor
(GHRH-R) via activation of the phosphoinositide 3-ki-
nase (PI3K)/Akt pathway. In fact, GHRH-induced car-
dioprotectionwas abolished by theGHRHantagonist JV-
1-36 and by a specific Akt inhibitor. ERK1/2 and adenylyl
cyclase/cAMP/protein kinase A signaling were also in-
volved (9). The direct action of GHRH, which appears to
be without known side effects (10, 11), offers advantages
in comparison with ghrelin and other GHS, whose phar-
macologic potential is reduced by their pleiotropic actions
(12), with a high risk of unexpected side effects. More
recently, the cardioprotective effects of GHRH have been
confirmed also in vivo. Indeed, a long-lasting treatment
with theGHRHagonist JI-38 after both acutemyocardial
infarction (MI) (10) and chronic cardiac injury (13) im-
proved cardiac performance and decreased infarct size,
through GH/IGF-I-independent and GHRH-R-depen-
dent mechanisms. However, the in vivo scenario does not
allow an adequate evaluation of the actual GHRH tar-
get(s), because of “disturbing” events, such as endothelial/
neutrophil interaction and neurohormonal responses to
MI, which can interfere with its cardioprotective effects
(14). Furthermore, the in vivo studieswere not designed to
reduce lethal reperfusion injury, because GHRH was ad-
ministered 2 hours (10) or 1 month (13) after MI. This is
far from the therapeutic window for reperfusion injury,
whichoccurs in the very early reperfusionphase, ie,within
the first minutes after reflow (15, 16). In fact, growth fac-
tors, such as IGF-I and vascular endothelial growth factor,
were found to promote cardioprotection, when given at
early reperfusion, through theRISKpathway (7,17). It has
been suggested that, in view of its clinical application, a
treatment performed at the onset of myocardial reperfu-
sion appears to be more feasible than pretreatment (18,
19). Based on the foregoing, we hypothesized that GHRH
given at the onset of reperfusionwould reducemyocardial
reperfusion injury. Therefore, in the present study, we in-
vestigated the cardioprotective effects of GHRH, admin-
istered at early phase of reperfusion in isolated rat hearts.
Infarct size and cardio-hemodynamic performances were
assessed as end points of themyocardial damage. Involve-
ment of GHRH-R and activation of cardioprotective sig-
naling pathways were also investigated.
Cardioprotective pathways have been shown to con-
verge on mitochondria via activation of mitochondrial
ATP-dependent potassium (mKATP) channels, which gen-
erate small amounts of reactive oxygen species to prevent
mitochondrial permeability transition pore (mPTP) open-
ing (20). Therefore, mitochondria serve as both triggers
andend-effectorsofprotection. In fact, either activationof
mKATP or inhibition of mPTP opening prevent the release
of apoptotic signals into the cytosol, contributing to car-
diomyocyte survival (21). Moreover, mPTP opening has
been shown to cause the release of mitochondrial nicotin-
amide adeninedinucleotide (NAD), andduringpostisch-
emic reperfusion, mitochondrial NAD is strongly re-
duced, in a process that is prevented by mPTP inhibitors
(22). This suggests that the preservation of mitochondrial
NAD is associated with protection from myocyte death
and that PTP plays a key role in this process (23, 24).
Therefore, because NAD is reduced after the mPTP
opening, we also tested the hypothesis that treating iso-
lated hearts with GHRH would lead to an increase in the
NAD to reduced nicotinamide adenine dinucleotide
(NADH) ratio in the postischemic phase.
GHRH effects were also assessed on phosphorylation
of AMP-activated protein kinase (AMPK), which plays a
central role in themetabolic response of the heart to stress
and in the heart increases ischemic glucose uptake and
limits myocardial injury and apoptosis (25–27). Finally,
because transcription factor signal transducer and activa-
tor of transcription-3 (STAT-3) is part of the survivor ac-
tivating factor enhancement (SAFE) pathway, which also
converges on mitochondria during protection (28–30),
STAT-3 activation by GHRH was also investigated.
Materials and Methods
Reagents
The chemicals and inhibitors were purchased from Sigma-
Aldrich (Milano, Italy). Rat GHRH (GHRF, 1-44), was from
Phoenix Peptides (Karlsruhe, Germany), and reagents to assess
MIwere fromMerck (Milano, Italy). JV-1-36was from Bachem
(Bubendorf, Switzerland). P-ERK1/2, P-Akt (Ser473), Phospho
(P)-endothelial nitric oxide synthase (eNOS) (Ser1177), P-gly-
cogen synthase kinase (GSK)-3 (Ser9), P-STAT-3 (Tyr705),
P-AMPK (Thr172), and total antibodies were from Cell Sig-
naling Technology (Euroclone, Milano, Italy).
Animals
MaleWistar rats (body weight, 450–550 g) provided by Jan-
vier (Le Genest Saint Isle, France) received human care in com-
pliance with the Italian law (DL-116, January 27, 1992) and in
accordance with the Guide for the Care and Use of Laboratory
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Animals published by the United States National Institutes of
Health (NIH Publication No. 85-23, revised 1996). The scien-
tific project has been supervised and approved by the Italian
Ministry of Health (Rome, Italy) and by the Ethical Committee
of the University of Torino.
Isolated heart perfusion
The methods were similar to those previously described (31,
32). Animals were anesthetized with urethane (1 g/kg ip); 10
minutes after heparin treatment, theywere decapitated, the chest
wasopened, and theheartwas rapidly excised. Isolated rat hearts
were weighed, attached to the perfusion apparatus, and retro-
gradely perfused with oxygenated Krebs-Henseleit (K-H) buffer
(127mMNaCl,17.7mMNaHCO3,5.1mMKCl,1.5mMCaCl2,
1.26mM MgCl2, and 11mM D-glucose), gassed with 95% O2
and 5%CO2. A constant flowwas adjusted with a proper pump
to obtain a typical coronary perfusion pressure (CPP) of 80–85
mm Hg during the initial part of stabilization. Thereafter, the
same flow level (91mL/ming)wasmaintained throughout the
experiment. A small hole in the LVwall was performed to allow
drainage of the thebesian flow, and a polyvinyl-chloride balloon
was placed into the left ventricle and connected to an electro-
manometer for recording of LV pressure (LVP) (developed LVP
[dLVP]). The balloon was filled with saline to achieve an end-
diastolic LVP (LVEDP) of 5 mm Hg. CPP, coronary flow, and
LVPwere continuouslymonitored to assess the conditions of the
preparation. The hearts were electrically paced at 280 bpm and
kept into a temperature-controlled chamber (37°C).
I/R induction on isolated hearts
Each heart was allowed to stabilize for 40 minutes, at which
time baseline parameters were recorded. After the stabilization
period, hearts were subjected to a specific protocol, which in-
cluded in all groups 30minutes of global no-flow ischemia. In all
groups, 30minutes of ischemiawere followed by a period of 120
minutes of reperfusion (see below). Pacing was discontinued on
initiation of ischemia and restarted after the third minute of
reperfusion (31, 32). Experimental pro-
tocols are described in Figure 1 and in the
Results section.
Assessment of myocardial injury
Infarct areas were assessed as previ-
ously described (31, 32). In brief, the
hearts were removed from perfusion ap-
paratus at the end of reperfusion, and the
left ventricles were dissected into 2- to
3-mm circumferential slices. After 20
minutes of incubation at 37°C in 0.1%
nitro-blue tetrazolium in phosphate buf-
fer solution, unstained necrotic tissue
was carefully separated from stained vi-
able tissue by an independent observer.
The necrotic mass was expressed as a
percentage of total LVmass. Although in
this model the whole heart underwent
normothermic ischemia, only the left
ventricles had a fixed volume and pre-
load; therefore, only the LV mass was
considered as risk area.
Assessment of mPTP opening
mPTP remains closed during ischemia and opens in the first
minutes of reperfusion, triggering cardiomyocyte cell death (21).
Mitochondria possess more than 90%of the total tissue content
of NAD. NAD is lost during reperfusion, being released dur-
ingmPTPopening. Therefore, lowNAD toNADHratio due to
reduction of NAD content in cardiac tissue is an indicator of
mPTPopening (23).Hearts (n4 for eachgroup)were subjected
to either 90 minutes perfusion only (Sham), to I/R only, or to
GHRH-Post. Quantification of NAD to NADH ratio was as-
sessed at 20minutes after the beginning of reperfusion according
to the manufacturer’s instructions using BioVision kits (BioVi-
sion, San Francisco, California). In brief, rat hearts were homog-
enized, cell debris was pelleted, and the resulting supernatant
used for the quantification of the NAD to NADH ratio using a
spectrophotometer (Asys UVM 340) at 450-nm OD.
Western blotting
Immunoblot analyses were performed as described (9). LV
samples were collected after 90 minutes of buffer perfusion
(Sham) and at the end of treatment during reperfusion (after 20
min) for all other groups. All tissues were snap frozen in liquid
nitrogen before being stored at80°C until protein extraction.
Nuclear and cytosolic proteinswere extracted from the hearts by
homogenization of the tissue in a lysis buffer as previously de-
scribed (28). Briefly, 50 g of total proteins for P-ERK, P-Akt,
P-eNOS, P-GSK-3, and P-AMPKwere resolved in 12% SDS-
PAGEand incubatedwith the specific antibody.Nuclear extracts
(50 g) were used for P-STAT-3 detection. Blots were reprobed
with antibodies against total ERK1/2, Akt, eNOS, GSK-3,
STAT-3, and AMPK for normalization.
Statistical analysis
Data are expressed as means  SE. Two-way ANOVA and
Tukey’s honestly significant difference for post-ANOVA com-
parisons were used to evaluate the statistical significance of the
Stabilization IschemiaI/R Reperfusion
40 min 30 min 120 min
Control Continuous K-H perfusion buffer 
190 min
GHRH-Post
+ inhibitors Stabilization Ischemia GHRH Reperfusion
(5 min) (20 min)
I/R
+ inhibitors Stabilization Ischemia Reperfusion
(5 min) (20 min)
GHRH-Post Stabilization Ischemia GHRH Reperfusion
20 min
Figure 1. Experimental protocols. Before ischemia, hearts were randomly allocated to 1 of the
experimental groups. Control hearts were buffer perfused for a total of 190 minutes. All other
experimental hearts underwent 40 minutes of stabilization, 30 minutes of ischemia, and 120
minutes of reperfusion. Although GHRH was infused during the initial 20 minutes of reperfusion
only, inhibitors were infused during the final 5 minutes of stabilization, as indicated by the
number within round brackets under the bars, and during the initial 20 minutes of reperfusion.
K-H, Krebs-Henseleit buffer.
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differences between groups. Postischemic recovery of pressure
was evaluated comparingboth the last point of the curves and the
areas under the curve (AUCs) of the different groups. Signifi-
cance was established when P  .05.
Results
GHRH-Post reduces infarct size
TodeterminewhetherGHRHgiven at reperfusionpro-
tects from I/R injury, we measured MI size in isolated
perfused hearts. Experimental protocols (Figure 1): 1) I/R
group (n 11), hearts were stabilized and subjected to I/R
only; 2) GHRH-Postconditioning (GHRH-Post) group
(n  7), GHRH (50nM) (9) was infused for 20 minutes
immediately after ischemia; 3) GHRH with inhibitors,
heartswere perfusedwithGHRHwith either JV-1-36 (JV-
1-36, 20nM, n  6) (9), 5-hydroxydecanoate (5-HD)
(100M, n  6) (33), atractyloside (ATRA) (20M, n 
6) (34), Wortmannin (WM) (100nM; n 6) (35), or tyr-
phostin-AG490 (AG490) (10M, n  6) (36) (perfusion
with inhibitors started 5minutes before ischemia and con-
tinued during the early 20 minutes of reperfusion in the
presence of GHRH-Post [50nM]); and 4) in the groups
treated with inhibitors only (n  6, for each group), per-
fusion started 5 minutes before ischemia and continued
during the early 20 minutes of reperfusion.
Cardiacweight (1396 12mg; range, 1121–1912mg)
and the risk area, ie, LV mass (838 19 mg; range, 604-
1320 mg) were similar in all groups. Total infarct size,
expressed as a percentage of LVmass, was 61 5% in the
I/R group. GHRH-Post markedly reduced infarct size
(26 7%; P .05 vs I/R group) (Figure 2A). The GHRH
antagonist JV-1-36 (9) abolished GHRH-Post-induced
cardioprotection (infarct size, 74  7%), suggesting
GHRH-R-mediated mechanisms. Similarly, GHRH-Post
hearts treated with either the mKATP channel blocker,
5-HD (33), the selective opener of mPTP, ATRA (34), the
PI3K/Akt inhibitor WM (35), or the Janus kinase (JAK)/
STAT-3 inhibitor AG490 (36) showed reduced cardio-
protection (infarct size: 59 12, 50 6, 61 4, and 62
6%, respectively) (Figure 2A), suggesting that GHRH-in-
duced cardioprotection involves activation of the mKATP
channels, PI3K/Akt, and JAK/STAT-3 pathways and at-
tenuation of mPTP opening. The antagonists/inhibitors
alone showed no effect on infarct size (Figure 2B).
GHRH-Post improves cardiac function
The hemodynamic parameters recorded at baseline
conditions, after ischemia or at the end of reperfusion are
reported in Table 1.
Coronary perfusion pressure
In all groups, CPP increased during reperfusion with
respect to the baseline level. GHRH-Post limited this in-
crease when given alone. This reduction was blunted by
the antagonists (Figure 3A). Of note, JV-1-36 alone also
limited perfusion pressure in reperfusion (Figure 3B). In
fact, among groups with coinfusion of GHRH-
Postinibitors, GHRH-PostJV-1-36 displayed lower
values of CPP (Figure 3A). The other antagonists/inhibi-
tors alone showed increase ofCPPduring reperfusion sim-
ilar to I/R group. Postischemic recovery of CPP was eval-
uated comparing the last point of the curves, which
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Figure 2. GHRH-Post reduces MI size in isolated rat hearts subjected
to 30 minutes of ischemia and 120 minutes of reperfusion. (A) Hearts
were treated with vehicle alone (I/R) or with GHRH (50nM) at the onset
of reperfusion (GHRH-Post), in either absence or presence of the
indicated antagonist/inhibitors. (B) Hearts treated with either vehicle
(I/R) or antagonists/inhibitors alone. (A and B) JV-1-36 (JV), 20nM; 5-
HD, 100M; ATRA, 20M; WM, 100nM; AG490 (AG), 10M. Infarct
size was determined by nitro-blue tetrazolium staining as detailed in
Materials and Methods. Results are expressed as percent of ventricular
mass and are the means  SE (*P  .05, **P  .01, ***P  .001 vs
GHRH-Post; ns, not significant vs I/R).
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correspond to 120minutes of reperfusion. These analyses
revealed that GHRH-Post and JV-1-36I/R groups pres-
ent a significant reductionofCPPwith respect to I/Rgroup
(P  .05 vs I/R group; not significant vs each other).
Diastolic and systolic function
Mechanical cardiac function was analyzed by measur-
ing LVP. Temporal changes in LVEDP, as well as percent
variation with respect to baseline of maximum rate of
decrease in LVP during diastole (dP/dtmin), dLVP, and
maximum rate of increase in LVP during systole (dP/dt-
max), are reported inFigure4,A–D, respectively.The insets
of these panels show the AUC during postischemic recov-
ery for all groups. I/R hearts showed a marked increase in
LVEDPanda strong limitationof the recovery of dP/dtmin,
dLVP, and dP/dtmax during reperfusion.
In GHRH-Post, LVEDP was strongly reduced when
compared with the I/R hearts (25 11 vs 49 8 mmHg,
P  .01) (Figure 4A). In both GHRH-Post and I/R, the
recovery of dP/dtmin during reperfusion was inversely re-
lated to the development of diastolic contracture. In fact,
dP/dtmin values recorded from GHRH-Post hearts at the
end of reperfusion were significantly increased with re-
spect to those of I/R (119  12 vs 40  6%, P  .01)
(Figure 4B), suggesting improved diastolic function.
Although in I/R hearts at the end of reperfusion dLVP
was only 35  11% of baseline, GHRH-Post markedly
improved its recovery during reperfusion (dLVPwas 92
18% of baseline, P  .01 vs I/R) (Figure 4C). Figure 4D
shows a similar trend for the recovery of dP/dtmax (I/R
hearts, 44  15; GHRH-Post, 105  13%; P  .01).
All the antagonists/blockers reduced GHRH-induced
protectiononsystolicanddiastolic function. Indeed,LVEDP
and dLVP values at the end of reperfusion in hearts treated
with JV-1-36, 5-HD, ATRA, WM, and AG490 were com-
parable with those from I/R hearts (Figure 4, A and C, re-
spectively). Similar effects were observed for dP/dtmin and
dP/dtmax (Figure 4, B and D, respectively). The analysis of
AUCs confirmed a significant improvement of diastolic
(LVEDP and dP/dtmin) and systolic (dLVP and dP/dtmax)
function in GHRH-Post group (Figure 4, insets in panels
A–D).Moreover, the AUCs of LVEDP, dP/dtmin, dLVP, and
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Figure 3. CPP during stabilization, ischemia, and reperfusion. Values
are expressed as percent of baseline (preischemic value) and are the
means  SE. (A) I/R, GHRH-Post, and GHRH coinfused with inhibitors.
(B) Inhibitors only. For comparative purpose are also reported I/R and
GHRH-Post groups. (A) *P  .05 for GHRH-Post group vs all other
groups; (B) *P  .05 for I/R vs GHRH-post and I/RJV-1-36; P  not
significant for I/R vs all other groups. Vertical dashed lines indicate the
beginning and the end of the 30-minute global ischemia. JV, JV-1-36.
Table 1. Hemodynamic Parameters Recorded Before Ischemia (ie, at the End of Stabilization) and at the End of
Reperfusion (ie, at the End of Experiments)
At the end of stabilization At the end of experiments
Group
CPP
(mm Hg)
dLVP
(mm Hg) dP/dtmax
LVEDP
(mm Hg) dP/dtmin
CPP
(mm Hg)
dLVP
(mm Hg) dP/dtmax
LVEDP
(mm Hg) dP/dtmin
Control 80  2 79  1 1710  79 6  1 1578  76 83  2 77  2 1698  69 8  1 1569  45
I/R 80  3 81  4 1594  15 5  1 1568  151 144  13a 26  3b 293  61b 49  2b 482  172b
GHRH-Post 79  1 78  3 1815  91 4  1 1466  63 101  9a 60  8a 1533  303 18  4a 1343  303
GHRHJV-1-36 78  2 75  2 1353  149 6  2 1403  93 123  12a 31  9b 973  211a 45  19b 835  91a
GHRH5-HD 77  1 77  1 1670  226 5  1 1317  235 143  8a 31  6b 851  90a 43  17b 771  73a
GHRHATRA 78  3 79  2 1573  17 4  1 1316  192 150  15b 16  5b 500  80b 54  29b 595  229a
GHRHWM 77  2 78  1 1700  98 6  1 1450  69 166  35b 14  4b 391  81b 38  8b 338  44b
GHRHAG490 79  1 76  2 1695  95 5  1 1490  89 173  15b 15  2b 429  60b 42  4b 350  19b
I/RJV-1-36 79  2 80  3 1772  96 6  2 1420  78 93  2a 26  3b 592  77b 52  1b 735  17b
I/R5-HD 81  3 78  2 1780  77 5  1 1405  92 134  15a 25  5b 310  80b 57  9b 495  229a
I/RATRA 81  1 77  1 1760  97 6  2 1410  70 147  12a 28  3b 297  77b 50  5b 535  17b
I/RWM 80  3 80  3 1701  89 4  1 1569  89 175  15b 15  4b 511  95b 45  6b 386  69b
I/RAG490 81  4 79  2 1698  55 5  1 1685  93 175  8b 19  1b 510  35b 34  2b 423  32b
a P  .05 vs values before ischemia.
b P  .01 vs values before ischemia.
1628 Penna et al GHRH Induces Cardioprotection via RISK and SAFE Endocrinology, April 2013, 154(4):1624–1635
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 02 March 2014. at 12:20 For personal use only. No other uses without permission. . All rights reserved.
C-50 0 50 100 150
25
50
75
100
125
150
Time (min)
dP
/d
t m
in
 (%
)
##
##
## ## ## ####
*
** ** ** ** **
D
0
5000
10000
15000
**
dP
/d
t m
ax
(A
U
C
)
** ** **
**
**
I/R
GH
RH
GH
RH
+J
V
GH
RH
+A
TR
A
GH
RH
+5
HD
GH
RH
+A
G
GH
RH
+W
M
-50 0 50 100 150
0
25
50
75
100
125
Time (min)
dP
/d
t m
ax
(%
) * * ** ** ** **
#
# # #
# #
#
A
-50 0 50 100 150
0
25
50
75
100
Time (min)
LV
ED
P
 (m
m
 H
g)
** **
**
**
**
##### ##ns
**
I/R
GH
RH
GH
RH
+J
V
GH
RH
+A
TR
A
GH
RH
+5
HD
GH
RH
+A
G
GH
RH
+W
M
0
5000
10000
**
 L
VE
D
P 
(A
U
C
) **
**
**
** **
B
0
5000
10000
15000
**
dL
VP
 (A
U
C
)
** ** **
**
**
I/R
GH
RH
GH
RH
+J
V
GH
RH
+A
TR
A
GH
RH
+5
HD
GH
RH
+A
G
GH
RH
+W
M
0
2000
4000
6000
8000
10000
12000
14000
dP
/d
t m
in
 (A
U
C
)
I/R
GH
RH
GH
RH
+J
V
GH
RH
+A
TR
A
GH
RH
+5
HD
GH
RH
+A
G
GH
RH
+W
M
**
** **
**
** **
-50 0 50 100 150
0
25
50
75
100
125
Time (min)
dL
VP
 (%
)
** * ** ** ** **
##
##
##
##
##
##
##
I/R
GHRH-Post
GHRH-Post+JV
GHRH-Post+5-HD
GHRH-Post+ATRA
GHRH-Post+AG490
GHRH-Post+WM        
I/R
GHRH-Post
GHRH-Post+JV
GHRH-Post+5-HD
GHRH-Post+ATRA
GHRH-Post+AG490
GHRH-Post+WM        
Figure 4. Effect of GHRH-Post on diastolic and systolic function. LVEDP (A) and dP/dtmin (B) during reperfusion in rat hearts undergoing 30
minutes of ischemia and 120 minutes of reperfusion. Results are expressed as absolute values (LVEDP) or as percent of baseline (preischemic value)
(dP/dtmin). (A) **P  .01 for GHRH-Post group vs I/R, GHRH-PostJV-1-36, GHRH-Post5-HD, GHRH-PostATRA, GHRH-PostWM, and GHRH-
PostAG490 group. #P  .05 and ##P  .001 for GHRH-Post vs I/R (single time points). (B) *P  .05 for GHRH-Post group vs GHRH-PostATRA
group; **P  .01 for GHRH-Post group vs I/R and GHRH-PostJV-1-36, GHRH-Post5-HD, GHRH-PostWM, and GHRH-PostAG490 group.
##P  .001 for GHRH-Post vs I/R (single time points). (C and D) dLVP (C) and dP/dtmax (D). Values are expressed as percent of baseline (preischemic
value). (C) *P  .05 for GHRH-Post group vs GHRH-PostATRA group; **P  .01 for GHRH-Post vs I/R, GHRH-PostJV-1-36, GHRH-Post5-HD,
GHRH-PostWM, and GHRH-PostAG490 group. ##P  .001 for GHRH-Post vs I/R (single time points). (D) *P  .05, for GHRH-Post group vs
GHRH-PostATRA and GHRH-PostJV-1-36 group. **P  .01 for GHRH-Post vs I/R, GHRH-Post5-HD, GHRH-PostWM, and GHRH-
PostAG490 group. #P  .05 for GHRH-Post vs I/R (single time points). Vertical dashed lines indicate the beginning and the end of the 30-minute
global ischemia. Insets show the AUC (**P  .01 vs GHRH-Post). JV, JV-1-36.
doi: 10.1210/en.2012-2064 endo.endojournals.org 1629
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 02 March 2014. at 12:20 For personal use only. No other uses without permission. . All rights reserved.
dP/dtmaxobserved inGHRH-Postplusantagonistsweresim-
ilar to those observed in I/R group.
Of note, in the hearts where the inhibitors/antagonists
were used alone, the recovery of diastolic and systolic
function was similar to that of I/R group (Supplemental
Figure 1, published on The Endocrine Society’s Journals
Online web site at http://endo.endojournals.org).
GHRH-Post induces activation of RISK and SAFE
pathways
The RISK pathway confers powerful cardioprotection
and is recruited by both ischemic preconditioning and
postconditioning (24, 37). There-
fore, the effects of GHRH-Post were
investigated on activation of main
components of the RISK pathway,
such as Akt, ERK1/2, and their
downstream targets eNOS and
GSK-3 (7, 8). Akt phosphorylation
on Ser473 in I/R hearts, which
showed a small but significant in-
crease as compared with Sham, was
further enhanced by GHRH-Post
(Figure 5A). GHRH-Post also in-
creased the activation of ERK1/2 as
compared with I/R alone, whereas
I/R per se had no effect with respect
to Sham (Figure 5B). Similarly,
GHRH-Post increased phosphoryla-
tion and thereby inhibition of
GSK-3 on Ser9, with respect to I/R
hearts. Conversely, phospho-GSK-3
was unchanged in I/R hearts as com-
paredwithSham(Figure5C).Phospho-
eNOS (Ser1177) levelswereunchanged
in I/R hearts as compared with Sham,
whereastheywerestrongly increasedby
GHRH-Post (Figure 5D).
STAT-3 is a key component of
the SAFE pathway, which, apart
from or in addition to RISK,
confers protection in both isch-
emic preconditioning and postcon-
ditioning (24, 28). GHRH-Post
increased nuclear STAT-3 phos-
phorylation on Tyr705. Phospho-
STAT-3 was unchanged in I/R
hearts, as compared with Sham
(Figure 5E).
Next, the effect of GHRH-Post
was assessed on activation of
AMPK, which has been shown to
regulate myocardial metabolism
during I/R and to reduce ischemic injury during postisch-
emic reperfusion (26). GHRH-Post increased phospho-
AMPK, whereas AMPK phosphorylation was unchanged
in I/R vs Sham (Figure 5F).
GHRH antagonist JV-1-36 inhibits GHRH-Post-
induced activation of RISK and SAFE pathways
Based on the finding that JV-1-36 inhibited GHRH-
Post-induced cardioprotection, we determined whether
JV-1-36 would also reduce GHRH-Post effect on acti-
vation of RISK and SAFE pathways. GHRH-Post-in-
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Figure 5. Effect of GHRH-Post on activation of RISK and SAFE pathways. Western blot analysis
was performed on lysates from LVs collected during reperfusion (after 20 min) of either Sham (no
I/R), I/R, or ischemic hearts, which were reperfused in the presence of GHRH (GHRH-Post). (Upper
panels) Phosphorylation of Akt (A), ERK1/2 (B), GSK-3 (C), eNOS (D), STAT-3 (E), and AMPK (F).
Equal protein loading was determined by reprobing with antibodies to the respective total
proteins (lower panels). Blots are representative of at least three independent experiments.
Graphs represent the densitometric analysis of phosphorylated proteins normalized to total
proteins and reported as percent of Sham. *P .05, **P .01, ***P .001; ns, not significant.
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duced phosphorylation of Akt, ERK1/2, GSK-3,
eNOS, STAT-3, and AMPK in I/R hearts was strongly
inhibited by JV-1-36 (Figure 6), suggesting that GHRH-
Post-induced cardioprotection involves GHRH-R sig-
naling and activation of downstream survival kinases.
JV-1-36 alone increased Akt and STAT-3 phosphory-
lation in I/R hearts, reduced that of eNOS, and showed
no effect on ERK1/2, GSK-3, and AMPK.
PI3K/Akt and STAT-3 inhibitors
reduce GHRH-induced activation
of RISK and SAFE pathways
Basedon the finding that theRISK
and SAFE inhibitors reducedGHRH
cardioprotective effects, we investi-
gated whether they would also pre-
vent GHRH-Post-induced activa-
tion of RISK and SAFE signaling
pathways. Phosphorylation of Akt
and GSK-3, which are both part of
the RISK pathway, was reduced in
GHRH-Post hearts treated with the
Akt inhibitor WM (Figure 7, A and
B). Moreover, AG490, the inhibitor
of STAT-3, which is involved in the
SAFE pathway, reduced not only
GHRH-Post-induced phosphoryla-
tion of STAT-3 but also that of Akt
(Figure 7, C and D). These results
strengthen the assumption that the
RISK and SAFE pathways are in-
volved in GHRH cardioprotective
effects.
Assessment of mPTP opening
The NAD to NADH ratio was
found similar in the Sham and
GHRH-Post groups (0.31  0.06
and 0.33  0.07, respectively, P 
not significant). However, it was sig-
nificantly reduced in the I/R group
(0.180.03,P .05) (Figure8), due
to a decrease in NAD content. This
result suggests that GHRH-Post pre-
vents NAD to NADH ratio de-
crease upon reperfusion by inhibit-
ing mPTP opening.
Discussion
This study shows that GHRH, given
at the onset of reperfusion, induces
cardioprotection through the phos-
phorylation/modulation of kinases included in the RISK
(Akt, ERK1/2, and GSK-3) and SAFE (STAT-3) path-
ways and inhibition of mPTP opening. Accordingly,
GHRHpreserved postischemicNAD levels;moreover, it
induced the phosphorylation of eNOS, a downstream tar-
get of Akt (38, 39), and of AMPK, a metabolic regulator
against oxidative stress (25–27). Finally, our findings sug-
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Figure 6. JV-1-36 inhibits GHRH-Post-induced activation of RISK and SAFE pathways. Western
blot analysis was performed on lysates from LVs of I/R hearts during reperfusion (after 20 min),
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gest that GHRH-R is required for the GHRH cardiopro-
tective action and for activation of the downstream sig-
naling pathways.
Small synthetic peptidyl or nonpeptidyl GHSs, as well
as ghrelin gene-derivedpeptides, have been shown to exert
protective effects against cell death and contractile dys-
function in I/R hearts, akin to ischemic preconditioning
(4–6, 40). We have recently reported similar activity for
GHRH,whenadministeredbefore the ischemicperiod (9).
Although preconditioning has significant cardioprotec-
tive effects, its clinical application is limited, because it
must be initiated beforemyocardial ischemia. Conversely,
postconditioning has highlighted the importance of inter-
vening at the onset of myocardial reperfusion to protect
the ischemic heart, a clinicallymore relevant timepoint for
intervention in patients with acute MI and undergoing
angioplasty (16, 18, 19). However, 2 recent studies using
an established ischemic PostC algorithm found no protec-
tion against infarct size (41, 42), suggesting that ischemic
postconditioning may not become broadly applicable in
clinical routine. Therefore, the trans-
lation to clinical use of pharmaco-
logical interventionmay bemore ap-
pealing. This assumption led us to
investigate whether GHRH exerts
comparable cardioprotective effects
alsowhenapplied at thebeginningof
reperfusion. Our present study con-
firms that, like other peptide media-
tors (17, 31), cytokines (28), or phar-
macological agents (27), GHRH
induces cardioprotection when ad-
ministered during the first phases of
reperfusion. This effect was clear-
cut, in particular, for improvement
of LVdP/dtmax and reduction of di-
astolic contracture, which has been
suggested as very good indicator of
I/R injury in isolated rat hearts sub-
jected to global ischemia (43). The
concentration at which this peptide
exhibits a protective effect is compa-
rable with that already shown for
GHSs, ghrelin (5, 40) or obestatin
(6), or GHRH itself when given be-
fore reperfusion (9).
Interestingly, the cardioprotective
effectofGHRHhasbeenrecentlycon-
firmed by Kanashiro-Takeuchi et al
(10) in vivo, where the long-lasting
treatment with the GHRH agonist
JI-38activatedmyocardial repair after
both acute MI and chronic ischemic heart disease (10, 13).
These studies suggested thatGHRHeffects involve cell-cycle
reentry, angiogenesis, and likely cardiac stem cell activation;
however, the signaling pathways triggered by GHRH were
not investigated. Kanashiro-Takeuchi et al (10) also showed
GHRH-R expression in rat heart and sarcolemmal mem-
brane of cardiomyocytes, in agreement with our previous
findings (9). Moreover, GHRH-induced cardioprotection
involved activation of GHRH-R, as demonstrated by use of
a selective receptor antagonist (13). Accordingly, we have
recently demonstrated that the GHRH antagonist JV-1-36
inhibits GHRH-induced survival in adult rat ventricular
myocytesandpreventsGHRH-inducedcardioprotectionbe-
fore the ischemic period in isolated rat heart (9). Here, JV-
1-36 reduced GHRH-Post cardioprotection and hampered
the activation of signal transduction cascades, further indi-
cating a key role for GHRH-R in GHRH-Post cardiopro-
tective effects.
Administration of GHRH to HeLA human cervical
cancer cells transfected with the GHRH-R has been pre-
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Figure 7. GHRH-induced activation of RISK and SAFE is reduced by PI3K/Akt and STAT-3
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viously shown to activate JAK2/STAT-3 pathway (44).
Importantly, GHRH antagonists are based on the se-
quence of the native GHRH and may therefore occasion-
ally display some agonistic effects. This could explainwhy
in the present study JV-1-36 alone slightly increased
STAT-3 phosphorylation in I/R hearts. In turn, the in-
crease of PI3K/Akt by JV-1-36 may result from activation
of survival mechanisms by the cells, to counteract the in-
crease of harmful signaling pathways, such as STAT-3.
The effects of both mKATP inhibition by 5-HD and
mPTP opening by ATRA in various models of infarct size
and postischemic mechanical recovery have already been
studied (32, 45). Our present observation that 5-HD and
ATRAabolish theprotective effect ofGHRHsuggests that
both activation of mKATP and mPTP closure play a rele-
vant role in GHRH-induced cardioprotection. In addi-
tion, the preserved myocardial NAD to NADH ratio in
GHRH-Post hearts further supports an involvement of
mPTP closure in GHRH-induced cardioprotection. Sev-
eral effectors of theRISKandSAFEpathways are involved
in the cardioprotection elicited by ischemic PostC, which
converge on mitochondria, and specifically on mPTP (24,
28, 34). Indeed, inhibition of mPTP at the onset of reper-
fusion has been found to strongly reduce MI size in both
laboratory and clinical settings (34, 46). Activation of
mKATP also plays an important role in cardioprotection
(20). KATP channels (both on sarcolemmal andmitochon-
drial membranes) are biosensors that enable detection of
metabolic distress signals and operate adjusting mem-
brane potential-dependent functions to match energetic
demands of the working heart (20, 47). Energy demand in
the heart is also linked to AMPK, which is activated in
response to stressors, such as ischemia (25). AMPK has
been shown to protect from ischemic injury, to reduce
infarct size, and to limit the development of cardiomyo-
cyte hypertrophy, through stimulation of glucose uptake,
as well as mitochondrial fatty acid uptake and oxidation
(25–27). AMPK activity in the heart is modulated by hor-
mones, such as adiponectin, leptin, and ghrelin, or cyto-
kines, likeTNF- (26). Furthermore,AMPKincreases glu-
cose uptake in skeletal muscle (48), suggesting beneficial
effects against insulin resistance. Here, we firstly show
that GHRH may not only open mKATP channels but also
activates AMPK during reperfusion, which further sup-
ports its cardioprotective action and suggests a role in
heart metabolism. GHRH-Post also increased the phos-
phorylation of eNOS, a well-known AMPK target in car-
dioprotection (49, 50). In addition, besides being a down-
stream target of the RISK pathway, NO has the potential
to inhibitmPTPopening,with the possible involvement of
mKATP (7). Interestingly, because GHRH induces vasodi-
lation, as inferred by GHRH-induced CPP reduction, it is
likely thatNOismainlyproducedwithin the endothelium.
In fact, NO is principally a paracrine effector, being syn-
thesized by 1 cell type to diffuse andmodify the biology of
neighboring cells (eg, smooth muscle and cardiomyo-
cytes). In particular, expression of eNOS within endothe-
lial cells exceeds that in cardiomyocytes by more than 4:1
(51), suggesting that a substantial degree of physiological
eNOS signaling in the cardiovascular tissues is paracrine.
Akt, which is also activated here by GHRH, has been
previously shown to phosphorylate eNOS (8, 39), further
contributing to the inhibition of the mPTP opening and
myocardium protection. Both Akt and ERK1/2 play im-
portant protective roles against reperfusion injury and are
part of the prosurvival RISK pathway. Their function in
postconditioning has been confirmed in both nondiseased
animal hearts and inpostinfarct remodeling (7, 24).More-
over, the cardioprotective role of the RISK pathway has
been confirmed in ex vivo studies in human atrial trabec-
ulae subjected to I/R injury (52).
We found here that GHRH also promoted phosphor-
ylation/inactivation of GSK-3. GSK-3 is a substrate of
prosurvival protein kinases, including Akt, ERK1/2, and
AMPK, and is a step towhichmultiple protective signaling
pathways converge (53). Furthermore,mPTP opening has
been shown tobe limitedbyphosphorylation/inhibitionof
GSK-3 (54); however, this effect has not been fully un-
derstood, and the role of GSK-3 in postconditioning is
controversial (24). Inhibition of PI3K/Akt signaling by
WM was found here to abrogate the cardioprotective ef-
fects of GHRH-Post and also to prevent GHRH-Post-in-
duced phosphorylation of PI3K/Akt and GSK-3. These
findings provide further evidence that GHRH displays its
cardioprotective activities through the RISK pathway.
GHRH also induced the phosphorylation of STAT-3,
which is included in the so-called SAFE pathway (28–30).
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Indeed,STAT-3mayalsoplayapivotalrole inthe interaction
between RISK and SAFE in PostC signaling (30). STAT-3
promotes cardioprotection via the phosphorylation and in-
activation of the proapoptotic factors Bad and Bax (28).
Moreover, pharmacological inhibition of STAT-3 was
found to abrogate both the PostC-induced phosphorylation
of STAT-3andAkt, suggesting thatAktmaybedownstream
of STAT-3 (29). Accordingly, we found here that inhibition
of STAT-3 byAG490 reduced bothGHRH-Post cardiopro-
tective effects, as well as GHRH-Post-induced Akt phos-
phorylation, suggesting close interaction between STAT3
andAkt in the cardioprotective signalingpathwaysactivated
byGHRH-Post.Recent data suggest that the SAFEpathway
may also target the mPTP, initially described as an end-ef-
fector of the RISK pathway (30).
In conclusion, the present study shows that adminis-
tration of nanomolar concentrations of GHRH in early
phase of reperfusion induces cardioprotection. GHRH
cardioprotective effect involves receptor-mediated activa-
tion of both RISK and SAFE pathways, as well as impor-
tant modulators of mitochondrial function and metabo-
lism. Interestingly, similarly to GHRH-R, GHRHmRNA
and protein have been found in peripheral tissues, includ-
ing the heart (9, 55). Therefore, local intracardiac GHRH
may also play a role in protecting the myocardium from
prolonged and excessive stress, suggesting potentially im-
portant implications in clinical settings.
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